P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.
Mark Bustoros,Romanos Sklavenitis-Pistofidis,Jihye Park,Robert A. Redd,Binyamin Zhitomirsky,Chip Stewart,Yu-Tzu Tai,Alex Barbera,François Aguet,Tarek H. Mouhieddine,Selina Chavada,David Soong,Cody J. Boehner,Carl Jannes Neuse,Andrew Dunford,Mahshid Rahmat,Adriana Peilla Glen,Eliezer M. Van Allen,Shaji Kumar,Efstathios Kastritis,Elizabeth A. Morgan,Jacob P. Laubach,Meletios A. Dimopoulos,Christopher Chiu,Paul G. Richardson,Kenneth C. Anderson,Nikhil C. Munshi,Kwee Yong,Lorenzo Trippa,Irene M. Ghobrial,Salomon Manier,Gad Getz +31 more
Journal ArticleDOI
Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis
Fredrik Schjesvold,Paul G. Richardson,Michel Attal,Thierry Facon,Adrian Alegre,Andrew Spencer,Artur Jurczyszyn,Kazutaka Sunami,Laurent Frenzel,Chang-Ki Min,Solenn Le-Guennec,Frank Campana,Helgi van de Velde,Samira Bensfia,Sara Bringhen +14 more
TL;DR: This subgroup analysis of ICARIA-MM examined efficacy and safety in elderly pts (≥75 years) compared with younger pts, finding progression-free survival (PFS) was significantly improved with Isa-Pd versus Pd.
Journal ArticleDOI
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Alessandra Larocca,Xavier Leleu,Cyrille Touzeau,Joan Bladé,Agne Paner,Maria-Victoria Mateos,Michele Cavo,Christopher Maisel,Adrian Alegre,Albert Oriol,Anastasios Raptis,Paula Rodriguez-Otero,Amitabha Mazumder,Jacob P. Laubach,Omar Nadeem,Anna Sandberg,Marie Orre,Anna Torrång,Nicolaas A Bakker,Paul G. Richardson +19 more
TL;DR: In this article, the authors showed that melphalan flufenamide (melflufen) plus dexamethasone treatment preserved health-related quality of life (HRQoL) in patients with RRMM.
Journal ArticleDOI
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
TL;DR: This review discusses the rationale for use of RVD as induction therapy and aims to provide guidance in prescribing this regimen in order to optimise efficacy while minimising the toxicities of treatment.
Journal ArticleDOI
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Paul G. Richardson,Fredrik Schjesvold,Katja Weisel,Philippe Moreau,Larry D. Anderson,Darrell White,Paula Rodriguez-Otero,Pieter Sonneveld,Monika Engelhardt,Matthew W Jenner,Alessandro Corso,Jan Dürig,Michel Pavic,Morten Salomo,Meral Beksac,Albert Oriol,Jindriska Lindsay,Anna Marina Liberati,Monica Galli,Pawel Robak,Alessandra Larocca,Münci Yağcı,Filiz Vural,Abraham S. Kanate,Ruiyun Jiang,Lara Grote,Teresa Peluso,Meletios A. Dimopoulos +27 more
TL;DR: In this article, the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs Vd by age, renal function, and high-risk cytogenetic abnormalities in patients with multiple myeloma at first relapse were evaluated.